Braveheart Bio (BRVE) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 21 64 sessions, August 6, 2026 to November 4, 2026
- Largest daily move
- -14.3% close of September 21, 2026
- 1-month change
- -5.5% closing prices, October 2, 2026 to November 4, 2026
Company Description
Braveheart Bio (NASDAQ: BRVE) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $1.8B.
BRVE has declined 5.5% over the past month. The last closing price was $20.11.
This page collects what Stock Titan holds for BRVE, including price data, latest news, SEC filings, insider trading activity, upcoming events, and short interest trends.
Stock Performance
Braveheart Bio (BRVE) closed at $20.11 on November 4, 2026. Over the past month, the price has lost 5.5%.
BRVE Metrics & Rankings
Price returns through November 4, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Braveheart Bio has 7 recent news articles, with the latest published 6 days ago. Of the recent coverage, 4 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, IPO, offering. View all BRVE news →
SEC Filings
Braveheart Bio has filed 10 recent SEC filings, including 3 Form 4, 2 Form SCHEDULE 13D, 1 Form 3, 1 Form SCHEDULE 13D/A. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all BRVE SEC filings →
Insider Radar
Insider buying activity at Braveheart Bio over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
Late-breaking presentation
Diastolic function presentation
Cardiac myosin webinar
NOBLEHEART trial start
LIONHEART interim results
Braveheart Bio has 5 upcoming scheduled events. The next event, "Late-breaking presentation", is scheduled for November 6, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the BRVE stock price.
Short Interest History
Short interest in Braveheart Bio (BRVE) currently stands at 4.9 million shares, up 18.8% from the previous reporting period, representing 19.2% of the float. Since August 2026, short interest has increased by 478.6%.
Days to Cover History
Days to cover for Braveheart Bio (BRVE) currently stands at 11.8 days, up 130.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since August 2026, the figure has increased by 804.6%. Across the settlements charted above, it has ranged from 1.3 to 11.8 days.
BRVE Company Profile & Sector Positioning
Braveheart Bio (BRVE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing BRVE often look at related companies in the same sector, including Vir Biotechnology, Inc. (VIR), Precigen, Inc. (PGEN), Agios Pharmaceuticals, Inc. (AGIO), Zenas BioPharma, Inc. (ZBIO), and Absci Corporation (ABSI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BRVE's relative position within its industry.